Why Tempus AI Skyrocketed This Week

Tempus AI stock surged 39.5% this week following positive Phase 3 trial results from Merck and Moderna for a jointly developed mRNA cancer vaccine combined with Keytruda immunotherapy. The gains were driven by Tempus's pending acquisition of Personalis, which developed the genomic tumor-profiling technology central to the vaccine's development. Despite the rally, Tempus remains down roughly 10% over the past year.

08/23/2026, 7:15 AM • The Motley Fool

A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know

Nadja West, a director at Tempus AI, sold 3,000 shares for $161,700 on August 14 under a pre-established Rule 10b5-1 trading plan set up in May. Four days later, the stock rallied 24% following news that Moderna and Merck's cancer vaccine succeeded in late-stage trials. West retained 34,981 shares worth ~$1.8 million. The sale timing appears coincidental as it was scheduled months in advance, and the company reported strong Q2 results with 22% revenue growth and its first GAAP profit.

08/22/2026, 8:19 AM • The Motley Fool

Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Trade

Tempus AI's Chief Legal Officer Andrew Polovin sold 30,075 shares worth $1.5 million in a non-discretionary transaction to cover tax withholding obligations from RSU vesting. The sale occurred during a 75% stock rally driven by positive results from a Moderna-Merck cancer vaccine trial validating Tempus's genomic sequencing technology. The company reported 22% revenue growth to $382.5 million last quarter and achieved its first GAAP profit, though it remains unprofitable on a TTM basis with -$254.4 million net income.

08/22/2026, 8:05 AM • The Motley Fool

Tempus AI's Data Chief Just Filed a Form 4. His Segment Grew 28% Last Quarter.

Ryan Fukushima, CEO of Tempus AI's data business, sold 41,095 shares (~$2.0 million) on August 18 through a non-discretionary sell-to-cover transaction to satisfy tax withholding obligations from RSU vesting. Despite the sale, Fukushima maintains a substantial stake of approximately 624,000 total shares. His data segment showed strong growth with 28% year-over-year revenue increase to $93.2 million, outpacing the diagnostics division.

08/22/2026, 7:34 AM • The Motley Fool

PSNL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Personalis to Tempus AI

Law firm Wohl & Fruchter is investigating whether the Personalis board acted in shareholders' best interests regarding the proposed $16.25 per share sale to Tempus AI. Since the announcement on July 20, 2026, Personalis shares have fallen approximately 14% due to the deal's partial stock consideration and Tempus share price decline. Shareholders have expressed disappointment with the transaction.

08/04/2026, 2:04 PM • GlobeNewswire

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

Law firm Julie & Holleman is investigating Personalis' proposed acquisition by Tempus AI for $16.25 per share, raising concerns about fair value and potential conflicts of interest given Tempus' existing significant equity stake and strategic partnership with Personalis since 2023.

08/03/2026, 7:45 AM • GlobeNewswire

Is Tempus AI Stock a Buy After Its CEO Sold 250,000 Shares?

Tempus AI CEO Eric Lefkofsky sold 250,000 shares worth $10.5 million on July 28, 2026, reducing his stake by 4% through a pre-scheduled trading plan established in March. Despite the sale, Lefkofsky retains approximately 6.5 million shares. The article suggests this represents routine portfolio management rather than a loss of confidence, noting the company's strong Q2 2026 performance with 20% YoY revenue growth and 31% oncology volume growth, plus a strategic $1.5 billion acquisition of Personalis.

07/31/2026, 9:27 AM • The Motley Fool

Halper Sadeh LLC is Investigating Whether FNWD and PSNL are Obtaining Fair Deals for their Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating several companies for potential securities law violations and breaches of fiduciary duties related to proposed acquisitions. The investigations focus on whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests. The firm is seeking increased consideration, additional disclosures, and other relief on behalf of affected shareholders.

07/29/2026, 9:39 PM • GlobeNewswire

PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus

Julie & Holleman LLP is investigating Personalis Inc.'s proposed acquisition by Tempus AI for $16.25 per share. The law firm is concerned about potential conflicts of interest given Tempus' existing significant equity stake and strategic relationship with Personalis since 2023, and whether shareholders are receiving fair value for their shares.

07/20/2026, 11:54 AM • GlobeNewswire

Nano Dimension and Infinite Epigenetics Provide Additional Information Regarding Proposed Business Combination

Nano Dimension and Infinite Epigenetics announced a proposed business combination to create an AI-powered preventive health and diagnostics company. Nano Dimension's board selected Infinite Epigenetics after evaluating approximately 20 opportunities, citing its established epigenetics science, CLIA-certified laboratory, 120,000+ biological samples, and commercial revenue. The companies addressed concerns from shareholder Murchinson Ltd., emphasizing the transaction's strategic rationale, capital deployment plan, and board expertise. The combination values Nano at net cash plus a 20% premium and will be subject to shareholder vote.

06/16/2026, 7:43 PM • GlobeNewswire

16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart Gap

Ventripoint Diagnostics announced support for the newly formed Global Congenital Heart Disease Alliance (GCHDA), positioning its AI-powered VMS+ cardiac imaging platform to address a critical global healthcare gap. With 16 million people living with congenital heart disease and over 90% of children in lower-income countries lacking timely care, Ventripoint's vendor-agnostic technology delivers MRI-level accuracy from standard echocardiograms. The alliance will fund and place four VMS+ units, signaling commercial validation in a rapidly growing AI cardiology market projected to reach $14.2 billion by the mid-2030s.

06/16/2026, 9:11 AM • Benzinga

Great News: This Explosive Healthcare Stock Could Be a Powerful Artificial Intelligence Winner

Tempus AI is positioning itself as a healthcare AI winner with its growing data platform, AI tools, FDA progress, and pharma partnerships. However, the stock already reflects high expectations, making execution critical for investors seeking meaningful upside.

06/08/2026, 2:30 PM • The Motley Fool

Stock Market Today: Nasdaq 100 Slips As Broadcom Plunges, Bitcoin Hits 4-Month Lows

The Nasdaq 100 fell 0.7% as chip stocks stumbled, with Broadcom cratering 15% despite beating earnings due to weak AI-chip revenue guidance. The Dow Jones rallied 1.7% on defensive and financial strength, while the S&P 500 remained flat. Bitcoin hit a 4-month low at $61,310. Other tech stocks like CrowdStrike, Ciena, and Five Below also declined despite beating estimates, reflecting a 'beat-and-bleed' market dynamic. Healthcare and financial stocks led gains.

06/04/2026, 1:09 PM • Benzinga

Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery

Bristol-Myers Squibb announced a strategic partnership with Anthropic to deploy advanced AI capabilities across its operations, focusing on drug discovery and development in oncology and neuroscience. The collaboration will leverage AI, multimodal data, and Tempus' analytical platform to streamline research, clinical development, and manufacturing processes, aiming to improve trial design and patient population identification.

05/20/2026, 1:09 PM • Benzinga

Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts

Ventripoint Diagnostics has achieved multiple validation milestones in early 2026, including submitting its VMS+ 4.0 system to China's NMPA for expedited review, exhibiting at Europe's largest congenital cardiology conference, and establishing commercial partnerships for hospital deployment. The company is capitalizing on a shifting procurement environment where hospitals now demand economic proof alongside clinical accuracy for AI cardiac imaging solutions.

05/19/2026, 8:55 AM • Benzinga